Adverum Reports Fourth Quarter 2017 Financial Results

From the Adverum Biotechnologies, Inc. financial results for the fourth quarter ended 31 December 2017 and corporate update:

“We enter 2018 with significant momentum following a year of critical execution to transform Adverum into a clinical-stage company,” said Amber Salzman, Ph.D., President and CEO. “We plan to submit an Investigational New Drug Application with the FDA in the second half of 2018 for ADVM-053 in HAE. We begin this exciting year of clinical development and regulatory progress in a strong position, funded to execute our three lead programs through the end of 2019 with preliminary clinical data for at least two of these programs.”
(Source: Adverum)